FINWIRES · TerminalLIVE
FINWIRES

Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target

By

SAB Biotherapeutics (SABS) has an average rating of buy and mean price target of $11.33, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Craig Hallum Upgrades Backblaze to Buy From Hold, $16 Price Target

Craig Hallum Upgrades Backblaze to Buy From Hold, $16 Price Target

$BLZE
Research

Daiwa Downgrades JD.com to Hold From Buy, Adjusts Price Target to $27 From $47

JD.com (JD) has an average rating of overweight and mean price target of $39.89, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $26.32, Change: $-0.70, Percent Change: -2.61%

$JD
Research

Daiwa Downgrades PDD to Hold From Buy, Adjusts Price Target to $80 From $145

PDD (PDD) has an average rating of overweight and mean price target of $118.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $76.35, Change: $-1.77, Percent Change: -2.26%

$PDD